Analysen von Michael Leuchten

19.01.17 Novo Nordisk buy UBS AG
15.12.16 Bayer buy UBS AG
06.12.16 Bayer buy UBS AG
06.12.16 Novo Nordisk buy UBS AG
12.05.16 Sanofi overweight Barclays Capital
04.05.16 GSK overweight Barclays Capital
02.05.16 Novo Nordisk overweight Barclays Capital
04.02.16 Novo Nordisk overweight Barclays Capital
15.01.16 Roche overweight Barclays Capital
08.01.16 Novo Nordisk overweight Barclays Capital
28.07.15 Roche overweight Barclays Capital
12.02.15 Roche overweight Barclays Capital
26.07.10 Actelion overweight Barclays Capital